Home
Clinical Resources Search
PQI: Use of Belumosudil (Rezurock®) for the Treatment of Chronic Graft-Versus-Host Disease

Use of Belumosudil (Rezurock®) for the Treatment of Chronic Graft-Versus-Host Disease

Download PQI pdf 0.11MB

Last Updated: September 29, 2023

By: Megan Dillaman, PharmD, BCOP

About this PQI

The purpose of this PQI is to discuss the use of belumosudil (Rezurock®) in the management of chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation. Belumosudil was approved by the United States Food & Drug Administration (FDA) in 2021 with indication for use in patients ≥ 12 years of age with cGVHD after two or more prior systemic therapies.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Graft Versus Host Disease (GVHD)

PQI

Frequently Searched

Supported by

Use of Belumosudil (Rezurock®) for the Treatment of Chronic Graft-Versus-Host Disease

About this PQI

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Epcoritamab (epcoritamab-bysp) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

The PQI Podcast S8 Ep 11: Honoring Her Legacy: A Conversation with Miss America 2024

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

Readiness Tracker

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Treatment Support Kit: Regorafenib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Ibrutinib Dosing Optimization

PQI: Ibrutinib (Imbruvica®) Management in Pediatric Patients

PQI: Ibrutinib (Imbruvica®) Management

The PQI Podcast S8 Ep 11: Honoring Her Legacy: A Conversation with Miss America 2024

PQI: Epcoritamab (epcoritamab-bysp) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting